Skip to main content

FIGURE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Publication ,  Other
Abou-Alfa, GK; Geyer, SM; Nixon, AB; Innocenti, F; Shi, Q; Kumthekar, P; Jacobson, S; El Dika, I; Yaqubie, A; Lopez, J; Huang, B; Tang, Y-W ...
March 7, 2024

<p>Kaplan–Meier curves for the OS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 1.14 for those with HCV-UN (vs. HCV-d), 95% CI: 0.58–2.23 (<i>P</i> = 0.70).</p>

Duke Scholars

DOI

Publication Date

March 7, 2024
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Abou-Alfa, G. K., Geyer, S. M., Nixon, A. B., Innocenti, F., Shi, Q., Kumthekar, P., … Venook, A. P. (2024). FIGURE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. https://doi.org/10.1158/2767-9764.25359921

DOI

Publication Date

March 7, 2024